Search that creates report cards
When a study is not already indexed, the search flow can ingest it and turn it into an internal TrialSignal report preview.
Diligence-ready clinical trial intelligence
Search public trial registries, index missing studies, compare sponsors and assets, and unlock source-linked reports with AI-assisted analysis and IP context.
Registry-first
source provenance
AI-assisted
normalization
PDF-ready
analyst reports
Indexed report
Source record verified
Sponsor and phase extracted
Patent landscape queued
Analyst workspace
01
Search registries02
Index reports03
Export diligenceProduct scope
Visitors can test public search before registration. Registered users can unlock individual reports, buy credits or subscribe for folders, exports, AI Q&A and patent enrichment requests.
When a study is not already indexed, the search flow can ingest it and turn it into an internal TrialSignal report preview.
Each report separates sponsor, indication, intervention, outcomes, eligibility, contacts, source freshness, IP status and AI analysis.
Pay per report, buy project credits or subscribe monthly without committing to enterprise-priced intelligence platforms.
Recently indexed trial reports
Bladder Exstrophy-Epispadias Complex · Target: Platelet-rich fibrin (PRF) as a biological adjunct in surgical repair, enhancing wound healing through growth factors and cytokines derived from autologous blood.
Type 1 Diabetes · Target: Continuous Glucose Monitoring Devices (CGMs) for diabetes management
Prostatic Neoplasms · Target: Docetaxel acts as a microtubule inhibitor, enhancing radiosensitivity in prostate cancer cells.
Adrenal Gland Pheochromocytoma · Target: Poly (ADP-ribose) polymerase (PARP) inhibition and DNA damage via alkylating agent mechanism.
Chronic Myelogenous Leukemia in Blast Crisis · Target: Aurora kinase and BCR-ABL
Retroperitoneal Sarcoma · Target: Liposomal bupivacaine injection (Quadratus Lumborum Block)
Actinic Keratosis · Target: Ingenol Mebutate (mechanism of action involves inducing cell death in keratinocytes and promoting local immune response)
Colorectal Liver Metastasis · Target: Not specified; focuses on the modulation of surgical stress response through exercise training in colorectal liver metastases patients.
Solid Tumors · Target: GITR (Glucocorticoid-Induced TNFR-Related Protein) and PD-1 (Programmed Cell Death Protein 1)
Prostate Cancer · Target: Gonadotropin-releasing hormone (GnRH) receptor
How it works
Search structured public trial records with NCT identifiers, sponsor fields and direct ClinicalTrials.gov source links.
Normalize targets, therapeutic modalities and indications while preserving raw registry values for auditability.
Open source-linked previews and upgrade when you need folders, exports, IP analysis and report Q&A.
Report anatomy
Every report separates registry facts, normalized fields, AI analysis and IP research status so users can see what is sourced, what is inferred and what still needs professional validation.
Open sample reportSource & freshness
NCT ID, ClinicalTrials.gov link, source update date, internal sync and provenance badges.
Protocol intelligence
Study design, outcomes, eligibility, interventions, contacts and registry-derived fields.
Patent/IP layer
Verified patent rows when available, broader asset landscape and enrichment request status.
Analyst export
Branded PDF-ready structure for meetings, diligence notes and folder-level synthesis.
What premium unlocks
A structured asset view with sponsor, indication, intervention, outcomes, eligibility, contacts, source freshness and premium AI context.
Verified patent rows when available, plus clearly separated patentability and freedom-to-operate research notes for analyst follow-up.
A branded report export designed for meetings, with provenance, taxonomy, executive summary, source sections and research disclaimers.
Save multiple trials into a pipeline and generate a multi-report brief comparing readouts, sponsors, risks and next diligence checks.
Simple pricing
Founders offer
5-day premium trial with code FOUNDERS5
Try unlimited reports, folders, AI assistant and exports before the €149/month subscription starts.
Single report
€29 one-time
Unlock one full source-linked report when you need a fast answer.
Credit bundles
€99, €249 or €599
Buy 5, 15 or 50 report credits for project-based research without recurring billing.
Monthly access
€149/month
Unlimited reports, folders, AI assistant, exports and multi-report synthesis.
Public sample
This example links back to the original registry source and includes the latest available source or internal indexing timestamp.
The study conducted by the National Children's Medical Center in Uzbekistan evaluates the use of autologous platelet-rich fibrin (PRF) in bladder exstrophy repair, a rare pediatric condition. With a small patient population of 20, the trial aims to demonstrate a reduction in postoperative complications, particularly penopubic fistula formation. If successful, this could position PRF as a valuable adjunct in pediatric urology, potentially expanding its application in other surgical contexts. The market for advanced wound healing products is growing, driven by increasing surgical procedures and a focus on reducing complications. However, the limited scope of this trial may restrict immediate commercial viability without further studies to validate findings across larger populations. Competitive analysis should consider existing biological and synthetic alternatives in wound healing.
Source: ClinicalTrials.gov
Timestamp: Jul 02, 2026
Sponsor: National Children's Medical Center, Uzbekistan
Modality: protein therapy
Trust boundaries
Important notes
TrialSignal provides software for professional research triage using public clinical trial records, automated normalization and clearly marked AI-assisted analysis. Platform outputs are informational and should be independently verified against primary sources.
Reports, patent notes, AI summaries and folder analyses are not medical advice, legal advice, regulatory advice, investment advice, patentability opinions or freedom-to-operate opinions. Users remain responsible for decisions and for obtaining qualified professional review where needed.
The current contracting and product operator is identified as TrialSignal. Replace this operational notice with counsel-reviewed legal entity, jurisdiction, refund and compliance language before broad commercial launch.